WANY
VRTX icon

Wealthspire Advisors (New York)’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$400K Sell
895
-930
-51% -$434K ﹤0.01% 646
2025
Q4 		$827K Buy
1,825
+1,382
+312% +$596K 0.01% 471
2025
Q3 		$173K Sell
443
-438
-50% -$183K ﹤0.01% 843
2025
Q2 		$392K Buy
881
+151
+21% +$69.6K ﹤0.01% 602
2025
Q1 		$354K Sell
730
-19
-3% -$8.85K ﹤0.01% 598
2024
Q4 		$302K Sell
749
-43
-5% -$19.9K ﹤0.01% 642
2024
Q3 		$368K Buy
792
+159
+25% +$76.4K ﹤0.01% 573
2024
Q2 		$297K Sell
633
-108
-15% -$46.9K ﹤0.01% 545
2024
Q1 		$310K Sell
741
-228
-24% -$96.4K ﹤0.01% 514
2023
Q4 		$394K Buy
969
+310
+47% +$115K 0.01% 455
2023
Q3 		$229K Sell
659
-1
-0.2% -$350 ﹤0.01% 536
2023
Q2 		$232K Buy
+660
New +$222K ﹤0.01% 498
2023
Q1 		– Sell
-833
Closed -$241K – 598
2022
Q4 		$241K Buy
+833
New +$254K ﹤0.01% 505
2021
Q2 		– Sell
-2,714
Closed -$583K – 662
2021
Q1 		$583K Sell
2,714
-88
-3% -$19.3K 0.01% 356
2020
Q4 		$662K Buy
2,802
+794
+40% +$182K 0.02% 262
2020
Q3 		$546K Buy
2,008
+117
+6% +$32.3K 0.03% 172
2020
Q2 		$549K Sell
1,891
-438
-19% -$119K 0.04% 147
2020
Q1 		$554K Buy
2,329
+1,335
+134% +$306K 0.02% 278
2019
Q4 		$218K Buy
+994
New +$201K 0.02% 192
2019
Q1 		– Sell
-220
Closed -$36K – 779
2018
Q4 		$36K Buy
+220
New +$38.1K ﹤0.01% 230

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wealthspire Advisors (New York)'s VRTX Position: Q1 2026 in Review

Wealthspire Advisors (New York) reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q1 2026, selling an estimated $434K and leaving 895 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #646.

Wealthspire Advisors (New York) first reported a position in VRTX in Q4 2018 and has held it in 20 quarters since. The position peaked at $827K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Wealthspire Advisors (New York) held 895 shares of Vertex Pharmaceuticals worth $400K as of Q1 2026.
  • Wealthspire Advisors (New York) sold 930 Vertex Pharmaceuticals shares in Q1 2026, an estimated $434K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #646 holding.
  • Wealthspire Advisors (New York) first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 20 quarters since.
  • Wealthspire Advisors (New York)'s Vertex Pharmaceuticals position peaked at $827K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.